Inhibition of DNA replication and induction of S phase cell cycle arrest by G-rich oligonucleotides.
The discovery of G-rich oligonucleotides (GROs) that have non-antisense antiproliferative activity against a number of cancer cell lines has been recently described. This biological activity of GROs was found to be associated with their ability to form stable G-quartet-containing structures and their binding to a specific cellular protein, most likely nucleolin (Bates, P. J., Kahlon, J. B., Thomas, S. D., Trent, J. O., and Miller, D. M. (1999) J. Biol. Chem. 274, 26369-26377). In this report, we further investigate the novel mechanism of GRO activity by examining their effects on cell cycle progression and on nucleic acid and protein biosynthesis. Cell cycle analysis of several tumor cell lines showed that cells accumulate in S phase in response to treatment with an active GRO. Analysis of 5-bromodeoxyuridine incorporation by these cells indicated the absence of de novo DNA synthesis, suggesting an arrest of the cell cycle predominantly in S phase. At the same time point, RNA and protein synthesis were found to be ongoing, indicating that arrest of DNA replication is a primary event in GRO-mediated inhibition of proliferation. This specific blockade of DNA replication eventually resulted in altered cell morphology and induction of apoptosis. To characterize further GRO-mediated inhibition of DNA replication, we used an in vitro assay based on replication of SV40 DNA. GROs were found to be capable of inhibiting DNA replication in the in vitro assay, and this activity was correlated to their antiproliferative effects. Furthermore, the effect of GROs on DNA replication in this assay was related to their inhibition of SV40 large T antigen helicase activity. The data presented suggest that the antiproliferative activity of GROs is a direct result of their inhibition of DNA replication, which may result from modulation of a replicative helicase activity.
Xu
X
X
Human Molecular Biology Group, James Graham Brown Cancer Center, Department of Medicine, University of Louisville, Louisville, Kentucky 40202, USA.
Hamhouyia
F
F
Thomas
S D
SD
Burke
T J
TJ
Girvan
A C
AC
McGregor
W G
WG
Trent
J O
JO
Miller
D M
DM
Bates
P J
PJ
D017209:Apoptosis; D002453:Cell Cycle; D002455:Cell Division; D002460:Cell Line; D004247:DNA / Q000096:biosynthesis* / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005434:Flow Cytometry; D006151:Guanosine / Q000737:chemistry; D006367:HeLa Cells; D006801:Humans; D020287:In Situ Nick-End Labeling; D009841:Oligonucleotides / Q000737:chemistry*; D010750:Phosphoproteins / Q000494:pharmacology; D011485:Protein Binding; D016601:RNA-Binding Proteins / Q000494:pharmacology; D012259:Ribonuclease, Pancreatic / Q000378:metabolism; D016196:S Phase; D013997:Time Factors; D000097796:Nucleolin
D004247:DNA; D006151:Guanosine; D009841:Oligonucleotides; D010750:Phosphoproteins; D016601:RNA-Binding Proteins; D012259:Ribonuclease, Pancreatic; D000097796:Nucleolin